Haviland Kate has filed 4 insider transactions across 2 companies since June 2024.
Most recent transaction: a grant/award of 36000 shares of Fulcrum Therapeutics, Inc. ($FULC) on June 26, 2025.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| June 26, 2025 | Fulcrum Therapeutics, Inc. | $FULC | Haviland Kate | Not found | A | Stock Option (right to buy) | 36000 | $0.00 | 36,000.0000 | 61,984 | 9999.99% | 58.08% |
| June 9, 2025 | Bicara Therapeutics Inc. | $BCAX | Haviland Kate | Director | A | Stock Option (Right to Buy) | 23746 | $0.00 | 23,746.0000 | 16,805,524,000 | 9999.99% | 0.00% |
| Sept. 12, 2024 | Bicara Therapeutics Inc. | $BCAX | Haviland Kate | Not found | A | Stock Option (Right to Buy) | 23746 | $0.00 | 23,746.0000 | 580,109,000 | 9999.99% | 0.00% |
| June 17, 2024 | Fulcrum Therapeutics, Inc. | $FULC | Haviland Kate | Not found | A | Stock Option (right to buy) | 30000 | $0.00 | 30,000.0000 | 61,310 | 9999.99% | 48.93% |